title: [Endogenous endophthalmitis as a complication in erysipelas].
abstract: BACKGROUND
  Endogenous endophthalmitis is a devastating infection of the eye that leads to blindness in about two-thirds of patients. It results from the haematogenous spread of a microorganism from a focus of sepsis, mainly gastro-intestinal, genitourinary or cardiac.
  
  
  METHODS
  We describe the case of a diabetic subject presenting endogenous endophthalmitis following erysipelas of the leg due to Streptococcus agalactiae. The outcome was favourable thanks to prompt initiation of appropriate antibiotic treatment.
  
  
  CONCLUSIONS
  Endogenous endophthalmitis as a complication of a skin infection is a rare entity, with only about 30 reported cases in the literature. Awareness of this condition among dermatologists would allow prompt intervention, which is essential for sparing of the patient's eyesight.
authors.affiliation: Service de dermatologie, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France. Electronic address: camillevalette33@gmail.com.
authors.forename: C
authors.initials: C
authors.lastname: Paquier-Valette
authors.forename: V
authors.initials: V
authors.lastname: Cante
authors.forename: S
authors.initials: S
authors.lastname: Brassat
authors.forename: M
authors.initials: M
authors.lastname: Camus
authors.forename: C
authors.initials: C
authors.lastname: Bolac
authors.forename: G
authors.initials: G
authors.lastname: Guillet
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D002442:Ceftazidime / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004198:Disease Susceptibility; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D004886:Erysipelas / Q000150:complications* / Q000188:drug therapy; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D007402:Intertrigo / Q000150:complications / Q000188:drug therapy; D007866:Leg; D064704:Levofloxacin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications; D013292:Streptococcus agalactiae / Q000302:isolation & purification; D014606:Uveitis, Anterior / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000935:Antifungal Agents; D064704:Levofloxacin; D014640:Vancomycin; D015378:Imipenem; D002442:Ceftazidime
keywords: Diabetes mellitus; Diabète de type 2; Endogenous endophthalmitis; Endophtalmie endogène; Erysipelas; Streptococcus agalactiae; Érysipèle